Angiotensin II Research: What 73,807 Studies Show (2026) | RetatrutideCompare

Angiotensin II — 73,807 studies indexed on PubMed. Activates AT1 receptor (vasoconstriction, aldosterone release, sodium retention) and AT2 receptor (counter-regulatory). Half-life: ~15–30 seconds (native); 4 minutes for Giapreza infusion-corrected. FDA status: FDA-approved (Giapreza 2017).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Angiotensin II?

There are approximately 73,807 studies indexed on PubMed that mention Angiotensin II (Giapreza), based on a search last updated 2026-06-18.

Is Angiotensin II FDA-approved?

FDA status: FDA-approved (Giapreza 2017).

How does Angiotensin II work?

Activates AT1 receptor (vasoconstriction, aldosterone release, sodium retention) and AT2 receptor (counter-regulatory).

Reference facts

Also known as: Giapreza
Category: Neuropeptide & Other
Mechanism of action: Activates AT1 receptor (vasoconstriction, aldosterone release, sodium retention) and AT2 receptor (counter-regulatory).
Targets: AT1R, AT2R
Indications under research or approved: Septic / vasodilatory shock (Giapreza)
Regulatory status (reference entry): FDA-approved (Giapreza 2017)
Half-life: ~15–30 seconds (native); 4 minutes for Giapreza infusion-corrected
Sequence: DRVYIHPF
Sequence notes: Octapeptide; cleaved from Angiotensin I by ACE.
Molecular weight (Da): 1046
Originator / sponsor: La Jolla Pharmaceutical (Innoviva)
First reported: 1957

Primary References

ATHOS-3, NEJM 2017

Explore research articles about Angiotensin II

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.